NEW YORK – CDK12-mutated prostate cancer is an aggressive subtype of the disease that usually yields poor outcomes to hormonal therapy, taxane therapy, and PARP inhibitors.
However, according to a study published this week in the JCO Precision Oncology, a portion of these patients could potentially respond to PD-1 inhibitors.